SMTI Stock - Sanara MedTech Inc.
Unlock GoAI Insights for SMTI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $86.67M | $64.99M | $45.84M | $24.14M | $15.59M |
| Gross Profit | $78.53M | $57.14M | $39.48M | $21.83M | $13.97M |
| Gross Margin | 90.6% | 87.9% | 86.1% | 90.4% | 89.6% |
| Operating Income | $-6,715,474 | $-4,215,153 | $-12,517,180 | $-7,376,157 | $-5,034,613 |
| Net Income | $-9,664,547 | $-4,303,197 | $-7,937,497 | $-7,921,914 | $-4,356,440 |
| Net Margin | -11.2% | -6.6% | -17.3% | -32.8% | -27.9% |
| EPS | $-1.14 | $-0.52 | $-1.00 | $-1.08 | $-0.76 |
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako's Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako's Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako's Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 26th 2025 | H.C. Wainwright | Reiterated | Buy | $51← $50 |
| December 23rd 2024 | H.C. Wainwright | Initiation | Buy | $50 |
| May 20th 2022 | Cantor Fitzgerald | Resumed | Overweight | $40← $45 |
Earnings History & Surprises
SMTIEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | $0.11 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.24 | $0.09 | +137.5% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.33 | $-0.23 | +30.3% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.31 | $-0.41 | -32.3% | ✗ MISS |
Q1 2025 | Mar 25, 2025 | $-0.19 | $-0.18 | +5.3% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.62 | $-0.34 | +45.2% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.21 | $-0.41 | -95.2% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.07 | $-0.21 | -200.0% | ✗ MISS |
Q1 2024 | Mar 25, 2024 | $-0.13 | $-0.03 | +76.9% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.13 | $-0.13 | 0.0% | = MET |
Q3 2023 | Aug 14, 2023 | $-0.13 | $-0.22 | -69.2% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.33 | $-0.20 | +39.4% | ✓ BEAT |
Q1 2023 | Mar 20, 2023 | $-0.26 | $-0.51 | -96.2% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.32 | $-0.18 | +43.8% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.28 | $-0.42 | -50.0% | ✗ MISS |
Q2 2022 | May 16, 2022 | — | $-0.41 | — | — |
Q1 2022 | Mar 30, 2022 | $-0.27 | $-0.48 | -77.8% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.18 | $-0.27 | -50.0% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | — | $-0.16 | — | — |
Q2 2021 | May 17, 2021 | — | $-0.17 | — | — |
Latest News
Sanara MedTech And Biomimetic Innovations Advance Strategic Alliance; Sanara Reaffirms Plans To Launch OsStic Bio‑Adhesive To US Commercial Market In Q1 2027
📈 PositiveHC Wainwright & Co. Maintains Buy on Sanara MedTech, Lowers Price Target to $36
📈 PositiveCORRECTION: Sanara MedTech Q3 EPS From Cont Ops $0.09 Beats $(0.21) Estimate
📈 PositiveSanara MedTech Q3 EPS $(3.40) Misses $(0.21) Estimate, Sales $26.334M Miss $26.625M Estimate
📉 NegativeSanara MedTech Discontinuing Operations Of Tissue Health Plus To Enhance Operating Efficiency, Reallocate Resources To Core Surgical Business
📈 PositiveSanara MedTech Appoints Seth Yon As President And CEO, Effective September 15, 2025, Succeeding Ron Nixon, Who Will Continue To Serve As Executive Chairman
➖ NeutralHC Wainwright & Co. Maintains Buy on Sanara MedTech, Raises Price Target to $54
📈 PositiveSanara MedTech Sales Jump 28 Percent
📈 PositiveFrequently Asked Questions about SMTI
What is SMTI's current stock price?
What is the analyst price target for SMTI?
What sector is Sanara MedTech Inc. in?
What is SMTI's market cap?
Does SMTI pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SMTI for comparison